Physician profile
Jonathan Bekisz
NPI 1144717059
$22,780.01
in general payments reported to CMS, 2019-2025
12 companies · $11K in 2025
The $11K reported for 2025 was more than what 96% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $12K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $20K · Food and Beverage: $2,385 · Education: $335 · Travel and Lodging: $59.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $20,000.00 |
| Food and Beverage | $2,385.17 |
| Education | $334.99 |
| Travel and Lodging | $59.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acumed LLC | $10,000.00 | 2024 | |
| Arthrex, INC. | $10,000.00 | 2025 | |
| Abbvie INC. | $840.08 | 2024-2025 | |
| Axogen | $525.29 | 2024-2025 | Axoguard Nerve Protector, Axoguard Ha+ Nerve Protector, Axoguard Nerve Cap |
| Trimed, INC. | $370.47 | 2024-2025 | |
| Integra Lifesciences Corporation | $341.91 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Medical Device Business Services, INC. | $334.99 | 2024 | |
| Suvon Surgical LLC | $246.78 | 2024-2025 | |
| Tela Bio, INC. | $50.12 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Kerecis Limited | $46.35 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Solventum Corporation | $19.04 | 2025 | V.A.C. Veraflo, V.A.C.Ulta, Prevena |
| Checkpoint Surgical, INC | $4.98 | 2025 | Checkpoint Stimulators |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bekisz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.